News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Thor Halfdanarson: Is it Effective and Safe to Use Lu-177 DOTATATE PRRT in Patients With NETs and Extensive Bone Metastases?
Thor Halfdanarson/mayoclinic.org
May 25, 2025, 05:33

Thor Halfdanarson: Is it Effective and Safe to Use Lu-177 DOTATATE PRRT in Patients With NETs and Extensive Bone Metastases?

Thor Halfdanarson, Medical Oncologist at the Mayo Clinic, shared a post on X:

“Lu-177 DOTATATE PRRT in patients with NETs and extensive bone metastases. Is it effective and is it safe?
It looks like the answer is yes to both and indeed, we use it frequently under such circumstances. Skeletal related events were 20%…”

Title: Clinical Outcomes of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Skeletal Metastases from Neuroendocrine Tumors: Insights from Real-World Experience

Authors: Kunal Ramesh Chandekar, Swayamjeet Satapathy, Sanjana Ballal, Madhav Prasad Yadav, Shubha Gadde Ravindra, Sameer Rastogi, Ranjit Kumar Sahoo, Chandrasekhar Bal

You can read the Full Article on Journal of Nuclear Medicine.

Thor Halfdanarson: Is it Effective and Safe to Use Lu-177 DOTATATE PRRT in Patients With NETs and Extensive Bone Metastases?

More posts featuring Thor Halfdanarson.

cancer Chandrasekhar Bal Kunal Ramesh Chandekar Madhav Prasad Yadav NETs OncoDaily Oncology Ranjit Kumar Sahoo Sameer Rastogi Sanjana Ballal Shubha Gadde Ravindra Swayamjeet Satapathy Thor Halfdanarson
Special Coverage
Blog
Jul 6, 2025, 02:27
A Public Hearing to Better Meet the Needs of Underserved Communities - European Cancer Organisation
Insight
Jul 5, 2025, 20:31
Diego A. Díaz García: Subclonal Immune Evasion in NSCLC
Blog
Jul 5, 2025, 20:15
Petros Grivas is Receiving 2025 Young Investigator Award
Blog
Jul 5, 2025, 20:00
Roberto Ferrara: Winter of Cancer Immunotherapy is Here
Blog
Jul 5, 2025, 19:42
Mario Balsa: TIME May Not Just Tell the Story - It Could Write the Prognosis STAR-01 at ESMOGI25
Blog
Jul 5, 2025, 19:18
Amol Akhade: CRC Screening Face-Off: Stool vs Blood
Blog
Jul 5, 2025, 18:53
Vivek Subbiah: How Clinical Trials Offer Hope for Those Facing Limited Options
Blog
Jul 5, 2025, 18:52
Saddened to Announce the Passing of Dr. Samantha Garza
Blog
Jul 5, 2025, 18:44
Because in a World Full of Opportunities, There’s No Time to Stop - CancerWorld
Blog
Jul 5, 2025, 18:38
Wongel Tsegaye: Crafting African Solutions for African Challenges
Blog
Jul 5, 2025, 18:26
Francisco J. Esteva: My New YouTube Channel Translates Breakthrough Cancer Care Into Plain, Evidence-based Guidance
Blog
Jul 5, 2025, 18:18
Don't Miss Out on the 2nd National Cancer Summit - National Cancer Institute of Kenya